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Hypertension is a major modifiable risk factor for car-
diovascular diseases (ischaemic heart disease, stroke, 
heart failure and ischaemic artery disease of the lower 
limbs) and the most epidemiologically significant 
cause of death in the world. At the same time, the 
prevalence of hypertension in Poland is constant-
ly increasing — according to the 2002 NATPOL 
study, it was 29% of adult Polish population [1]. 
In the second NATPOL study, the proportion of 
hypertensive patients increased to 32% [2] and in 
the WOBASZ II study in 2014 it reached 43% [3].
Large clinical trials indicate that effective blood 
pressure control is the most important condition 
for attaining the primary goal of treating hyperten-
sion, i.e., reduction of the mortality and incidence 
of cardiovascular events. Although the efficacy of 
blood pressure control in Poland has increased — 
according to the NATPOL programme, from 12% 
to 26% between 2002 and 2011 [2], and according 
to the WOBASZ program, from 10% to 23% be-
tween 2005 and 2014 [3], it is still low, which is 
mainly attributed to poor awareness of the presence 
and need for treatment of hypertension. Howev-
er, as indicated by the data from above-mentioned 
programmes, even among treated patients less than 
50% attain target blood pressure. The basic causes 
of low efficacy of hypertension control are patients’ 
poor adherence to lifestyle changes and low compli-
ance with pharmacotherapy, the therapeutic inertia 
of doctors and lack of significant progress in the de-
velopment of new antihypertensive agents in recent 
years. The progress in the efficacy of treatment of 
hypertension in Poland, which is observed despite 
these circumstances, is likely to be associated with 
the emergence of the single-pill combinations (SPCs) 
that improve compliance, reduce therapeutic inertia, 
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and are equivalent to progress in the pharmacother-
apy of hypertension. 
The use of combination drugs in Poland has risen 
steadily, reaching a total of 12% of all antihyperten-
sives in 2016, which is still unsatisfactory because the 
European average is twice as high. Hence the efforts 
of the Polish Society of Hypertension (PSH) to im-
prove the situation, expressed as highlighting the role 
of the SPCs in the 2011 and 2015 PSH Guidelines 
[4, 5], as well as cyclical publication of PSH experts’ 
position statement on the role of combination drugs 
(issued in 2009 and 2013) [6, 7]. 
The reasons for the publication of current expert 
consensus statement after 4 years are: the growing 
number of evidence on the benefits of SPC use in 
hypertension (also with concomitant dyslipidae-
mia), the extension of indications for their use in 
the hypertension management algorithm and the 
emergence in recent years, after the publication of 
PSH experts’ position statement in 2013, of new 
types of single-pill combinations available to doctors 
in Poland, including triple-drug combinations of 
antihypertensives and the so-called “hybrids” SPC 
containing not only antihypertensive drugs but also 
statins or acetylsalicylic acid (ASA). The current po-
sition statement of experts summarizes the progress 
of knowledge and practical application of single-pill 
combinations of antihypertensives in our country.
Single-pill combination of 
antihypertensive agents as an 
expression of progress in the 
pharmacotherapy of hypertension
The history of progress in the pharmacotherapy of hy-
pertension can be divided into several stages (Table I). 
After the invention in 1940s and 1950s of a number 
of sympatholytic drugs that were characterized by 
frequent adverse effects and were only an alternative 
to sympathectomy for severe malignant hyperten-
sion, the first modern antihypertensive agent was 
chlorothiazide — a diuretic introduced in 1957. 
Then, after 10 years, there was the “golden decade” 
of antihypertensive pharmacotherapy, when almost 
all major drug classes were invented, and the great-
est achievement of that time was the first inhibitor 
of angiotensin-converting enzyme (ACE), captopril, 
developed in 1977. Another important group of 
drugs were sartans which were introduced several 
years later. The last group of clinically relevant an-
tihypertensive drugs, used since 2000, are the renin 
inhibitors, but they were not more advanced than 
the most popular groups of renin-angiotensin-aldo-
table I. History of progress of antihypertensive pharmacotherapy
1937 Reserpine
1947 Hydralazine Surgical treatment 
(sympathectomy)1947 Ganglion-blocking drugs
1955 Guanethidine
1957 Thiazide diuretics (chlorothiazide)
1967 Spironolactone
1968 Methyldopa
1973 Beta-blockers (propranolol)
1970s Alpha 2 receptor agonists (clonidine)
1970s Nod-dihydropyridine calcium antagonists (vera-
pamil)
1975 Alpha-blockers (prazosin)
1975 Dihydropyridine calcium antagonists (nifedipine)
1977 ACE inhibitors (captopril)
1990 Sartans (losartan)
2000 Renin inhibitors (aliskiren)
po 2000 Modern combination drugs
sterone (RAA) system inhibitors and are practically 
not used in Poland. 
A review of scientific literature indicates that in 
the 21st century, despite many attempts, no new class 
of antihypertensive drugs that could improve the 
efficacy of blood pressure control (e.g., endothelin 
receptor antagonists, neutral endopeptidase inhib-
itors) has been introduced. Current research into 
new drug classes (including AT2 receptor agonists, 
aminopeptidase A and N inhibitors, prorenin inhib-
itors, natriuretic peptide receptor agonists, dopamine 
inhibitors, intestinal ion exchanger inhibitors Na+/
H+, group -SH donors opening potassium channels 
in vascular smooth muscles, direct cGMP stimula-
tors), although some are promising, do not provide 
a real basis for expecting significant clinical progress 
in the field of antihypertensive pharmacotherapy.
In conclusion, it seems that there will be a long 
pause in the introduction of new classes of antihy-
pertensive drugs, as the development of multiple 
drugs is in the I/II phase trials, without the guar-
antee of performing a large clinical trial meeting 
the evidence-based medicine (EBM) criteria (mul-
ticentre, prospective, comparative, randomized, 
double-blind, including a suitably large population, 
with an assessment of the drug effect on both blood 
pressure values and morbidity/mortality due to the 
assessed disease entity); however, some of them have 
identified other stronger indications (heart failure, 
pulmonary hypertension, diabetes mellitus). For ex-
ample, a new hybrid drug that affects both RAA 
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table II. Pros and cons for using antihypertensive single-pill com-
binations
Pros Cons
Fewer tablets to be taken
Lower doses of component drugs
Better tolerance
Comfort
Improved adherence
Lower costs
Rapidly achieved blood pressure control
Lower dosing flexibilit
Problems with esta-
blishing the source of 
adverse effects
and enzymes responsible for the degradation of 
natriuretic peptide (valsartan/sacubitril) has been 
approved for the treatment of heart failure, despite 
clear hypotensive effect.
The only noticeable progress in the pharmacother-
apy of hypertension in the last fifteen years, which 
may explain some increase in the effectiveness of 
blood pressure control in patients, is more common 
use of single-pill combinations of antihypertensive 
drugs. It is worth recalling that the SPCs have a long 
history in hypertensiology, but in the 1960s the 
preparations were based on drugs that are no longer 
used (e.g. reserpine + binazine, reserpine + dihydral-
azine). Hence, after a period of relatively low interest 
in SPCs, the introduction of modern SPCs at the 
beginning of the 21st century, the consolidation and 
extension of indications for combination therapy 
in the guidelines of scientific societies, the growing 
number of combination types, and the studies that 
have shown the benefits of SPCs have made these 
preparations increasingly popular among doctors. 
In Poland, in two years, the use of single-pill com-
bination drugs increased by 50%, reaching in 2016 
a total of 12% of all antihypertensive drugs. In this 
respect, further progress can be anticipated, as this is 
half that of the European average. 
Advantages of combination 
antihypertensive drugs
The balance of benefits and disadvantages of SPCs 
in antihypertensive therapy, which we presented in 
the 2009 expert position statement, is still valid in 
terms of benefits, which are after 8 years supported 
by more robust evidence; however, the disadvantages 
have been largely eliminated (Table II). 
The postulated at that time low dose flexibility 
was due to the fact that many SPC formulations 
had only one form. The SPCs were previously called 
FDCs — Fixed-Dose Combinations; the later name 
could suggest definite and unchangeable doses of 
components of the combination drug, which, with 
the current variety of potency of specific SPCs, is no 
longer true. Currently, most SPCs have from three 
(two-drug SPCs) to six (three-drug SPCs) forms, 
thereby allowing for a modification of therapy, 
which is especially important, considering current 
recommendation that in the event of insufficient 
blood pressure control the dose be increased after 
2–4 weeks. Potential difficulties in determining the 
source of adverse effects are limited to possible aller-
gic reactions, as the typical adverse effects of main 
groups of antihypertensive drugs are different and 
easily identifiable.
Some of the benefits of SPC (lower doses of indi-
vidual components and, therefore, better tolerance; 
more rapid pressure control) result from the advan-
tages of combination therapy. It should be reminded 
that the meta-analysis of the results of 42 controlled 
studies in 11,000 hypertensive patients showed that 
the additional antihypertensive effect of the combi-
nation of drugs from two different groups is almost 
five times greater than that of doubling the dose of 
a single drug [8]. This observation performed 8 years 
ago is of particular importance in the context of the 
analysis of results of the VALUE trial, indicating 
a significantly greater reduction in cardiovascular risk 
in those patients who have achieved blood pressure 
control within the first 6 months of treatment [9]. 
The advantages of combination therapy and SPC in 
terms of efficacy can now be significantly better uti-
lized due to the considerable extension of therapeutic 
indications in 2011 PSH guidelines and 2013 ESH 
guidelines [4, 5, 10]. 
Additional benefits, directly associated with the 
SPC, i.e. the smaller number of tablets and the con-
venience of dosage, translate into the most import-
ant advantage of the SPC which is improving the 
patient’s adherence in terms of both compliance and 
persistence. In this respect, the most referential study 
is meta-analysis of Gupta et al. [11], which included 
15 studies and more than 32,000 patients, demon-
strating that compared to control group, patients 
taking SPCs were characterized by better compliance 
(odds ratio [OR] 1.21, 95% confidence interval [CI] 
1.03–1.43) and a strong trend towards improved 
persistence (OR 1.54; CI 0.95–2.49), which translat-
ed into a greater reduction in blood pressure (4.1/3.1 
mmHg) and a trend toward more frequent normal-
ization of blood pressure (OR 1.30; CI 0.98–1.71). 
Many overviews and subsequent systematic reviews, 
meta-analyses and retrospective cohort studies, al-
though not all, confirm the benefits of SPC in treat-
ing hypertension with respect to improving patients’ 
compliance [12–14]. The Italian cohort study by 
Corraro et al. [15], which included 209,650 patients, 
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found that initiation of SPC therapy resulted in sig-
nificantly greater reductions in cardiovascular (11%), 
coronary (8%) and cerebrovascular (12%) risks com-
pared with monotherapy and stepped therapy. In the 
ACCOMPLISH study, switching from the current 
treatment with separate antihypertensive agents to 
SPC containing an ACE inhibitor resulted in a two-
fold increase in the efficacy of blood pressure control 
from about 40 to about 80%, regardless of the type 
of SPC used [16].
It should be assumed that the use of SPC may 
also contribute to the reduction of the second serious 
cause of low effectiveness of antihypertensive therapy, 
i.e. the therapeutic inertia of doctors, by reducing the 
concerns associated with concurrent use of several 
antihypertensive drugs.
Indications for the use of combinations 
of antihypertensive drugs and their role 
in ESH and PSH guidelines
The increased importance of combination antihy-
pertensive drugs is largely a consequence of the fact 
that scientific societies have extended the indications 
for the use of polytherapy in their guidelines. The 
basic premises of the use of combination antihyper-
tensive therapy have been stated in the 2007 ESH/
ESC 2007 guidelines and included too low propor-
tion of patients achieving blood pressure goal with 
monotherapy. It was suggested that in case of failure 
of monotherapy, the treatment should be changed 
to combination therapy and that preferred combi-
nations of two drugs should be used as first-line 
therapy in stage 2 and 3 hypertension and/or in 
patients with high cardiovascular risk [17]. In both 
cases, the 2007 ESH Guidelines assumed the possi-
bility of using the SPC. The next ESH Guidelines, 
issued in 2013 [10], strengthened this trend, by 
allowing in the treatment algorithm the possibil-
ity of early switching to combination therapy in 
patients with stage 1 hypertension and including 
a recommendation to consider initiating of antihy-
pertensive treatment with two-drug combination in 
stage 2 hypertension and the possibility of preferring 
combination therapy with SPC. However, both of 
these recommendations were of a relatively low class 
IIb, due to the level of evidence B, resulting from 
only one, according to opinion of the ESH experts, 
available relevant study — the Canadian STITCH 
trial. It is worth recalling that in this study, the treat-
ment based on the single-pill combination therapy 
provided better control of blood pressure and faster 
achievement of target values than the treatment al-
gorithm starting with monotherapy (65% vs. 53% 
with mean blood pressure reduction of 23/10 versus 
18/8 mmHg) [18].
In the opinion of the authors, recommendations 
for the use of SPC in the ESH Guidelines are too 
conservative. This document does not include data 
from the STRATHE study [19], in which initiation 
of antihypertensive treatment with a SPC was supe-
rior to stepped therapy (from monotherapy to com-
bination therapy) or sequential therapy (switching 
from ineffective drug to another one). Moreover, it 
is important to realize that the greatest advantage of 
SPCs over conventional combination therapy with 
separate agents, that is improved compliance that 
may translate into increased efficacy, is impossible to 
assess in accurately performed classic EBM studies 
which are based on the assumption of good compli-
ance and thus overstate it. Paradoxically, less appre-
ciated retrospective studies are free of this limitation.
It seems that a strong recommendation of SPC 
preference in combination therapy should be tak-
en on a common sense basis. Since combination 
drugs provide better patient compliance, this has to 
translate into better antihypertensive efficacy, as cur-
rently the low effectiveness of blood pressure control 
observed in studies such as the NATPOL study is 
explained by poor patient cooperation with the phy-
sician, although this statement is not confirmed by 
any direct evidence. 
This direction for the positioning of SPCs has 
been adopted by the authors of PSH Guidelines 
and its latest version issued in 2015 includes follow-
ing recommendation: “In combination therapy, it 
is worthwhile to use single-pill combination of two 
drugs, which allows for increasing treatment efficacy 
(STITCH and ACCOMPLISH), simplifying treat-
ment regimen and increasing patients adherence (me-
ta-analysis)” [5]. Already in the document published 
in 2011 [4], consideration was given in treatment 
algorithm to the possibility of early switching to 
combination therapy in patients with stage 1 hyper-
tension, and in 2015 PSH Guidelines this method 
of intensifying therapy is preferred. In addition, the 
antihypertensive treatment algorithm indicates that 
in each case of combination therapy a SPC should 
be preferred. A novelty resulting from ongoing but 
not yet completed clinical trials was the prediction 
in 2015 PSH Guidelines that “in the future, combi-
nation therapy with antihypertensive agents in doses 
smaller than the standard ones, available in two- and 
three-drug combinations may be an alternative for 
initiating the therapy in patients with stage 1 and 2/3 
hypertension respectively”. At present, such a new 
indication for starting the treatment in stage 1 hy-
arterial hypertension 2017, vol. 21, no. 3
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pertension with a single-pill combination of drugs 
in sub-standard doses has become a fact, besides the 
SPC containing perindopril and indapamide, also for 
the combination of perindopril and amlodipine (3.5 
mg/2.5 mg) after the publication of two clinical trials 
documenting the superiority of such SPC therapy 
over monotherapy with perindopril or amlodipine 
in typical doses [20] and over stepped therapy (sar-
tan –> sartan/amlodipine) in terms of the time to 
achieving target blood pressure and the percentage 
of well-controlled patients [21]. This new indication 
will probably be included in 2018 PSH Guidelines, 
but it can be recommended already.
Analysis of ESH experts’ lectures (Volpe, Wil-
liams) during this year’s ESH 2017 Annual Meeting 
in Milan suggests [22] that the next edition of the 
2018 ESH Guidelines may include major changes in 
the antihypertensive therapy algorithm, suggesting 
the need for initiation of pharmacologic treatment 
with combination therapy, i.e. SPC, in most patients 
with hypertension. 
Basic SPCs and individualization  
of their use
Currently there are eight types of two-drug SPCs 
and two types of three-drug SPCs, excluding the 
combinations of diuretics with different sites of ac-
tion within the nephron and hybrids which will be 
discussed separately. These numbers have doubled 
over the past 6 years, which is another proof of the 
intense development of this concept of treating hy-
pertension. Types of combination drugs introduced 
by the pharmaceutical companies are not accidental 
and almost perfectly reflect the principles of com-
bining antihypertensive drugs. All available types 
of SPC, except thiazide diuretics + beta-blockers, 
are combinations of drugs considered in 2015 PSH 
Guidelines as optimal due to complementary mecha-
nisms of action, proven cardiovascular risk reduction 
(as combination therapy or SPC), or unambiguous 
preference for both components in specific groups 
of patients. 
Of these, ACE inhibitor + calcium antagonist, 
ACE inhibitor + thiazide/thiazide-like diuretic, sar-
tan + thiazide diuretic and sartan + calcium antago-
nist should be considered as the key combinations 
used in the treatment of hypertension, which is sup-
ported by some arguments. The experience of Polish 
doctors in the use of these four combinations is the 
greatest because all of these drugs have been available 
for more than 10 years, meet the condition of pres-
ence of RAA inhibitor in combination, and three of 
them (Figure 1) have the largest body of evidence 
that they reduce cardiovascular risk in combination 
and provide a natural direction for initiation and/or 
intensification of therapy in uncomplicated arterial 
hypertension. It is worth noting that all of these are 
three-drug combinations including a RAA inhibitor 
+ calcium antagonist + thiazide/thiazide-like diuretic, 
which are considered to be obligatory in intensive 
treatment of uncomplicated arterial hypertension.
Among these four combinations, some preferences 
for their use can be outlined depending on patient’s 
global cardiovascular risk and metabolic status. These 
preferences are based on the observations described 
in 2015 PSH Guidelines suggesting that ACE in-
hibitors, due to additional bradykinin mechanism, 
are the most effective among all RAA inhibitors in 
reducing cardiovascular risk, which has been shown 
in recent meta-analyses [23–25], while thiazide-like 
diuretics due to additional vasodilatative mechanism 
are less likely to cause metabolic abnormalities, are 
more effective in reducing blood pressure and delay-
ing organ damage, and have greater body of EBM 
Figure 1. Percentage of positive outcome studies with basic combinations of antihypertensive drugs
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evidence for cardiovascular risk reduction in com-
bination with ACE inhibitors. The proportion of 
successful large clinical trials is different for these 
four combinations [10]. 
Combination of an ACE inhibitor + calcium an-
tagonist should be considered optimal in patients 
with high and very high cardiovascular risk. Un-
doubtedly, the position of this combination is due 
to the ACCOMPLISH trial in which such SPC was 
found to be more effective in reducing cardiovascu-
lar risk than SPC composed of an ACE-inhibitor 
+ thiazide diuretic [16]. Additionally, many clini-
cal studies have shown the organ-protective effect 
of such combination. Currently, four combinations 
of this type are available in Poland: perindopril + 
amlodipine, ramipril + amlodipine, lisinopril + am-
lodipine and relatively recent enalapril + lerkanidip-
ine. The strongest clinical evidence for the reduction 
of “hard” endpoints is available for the combination 
of perindopril + amlodipine due to the ASCOT 
study, the first large head-to-head trial in patients 
with uncomplicated arterial hypertension in which 
significant reduction in cardiovascular mortality was 
observed in patients receiving amlodipine + perin-
dopril compared to those treated with a beta-blocker 
+ a thiazide diuretic combination [26]. In addition, 
CAFÉ study, accompanying ASCOT study, showed 
a more effective reduction in central pressure. More-
over, the combination of perindopril + amlodipine in 
substandard doses, as one of very few along with the 
combination of perindopril and indapamide in the 
lowest doses, has the previously described indication 
for initiation of therapy in stage 1 hypertension [27].
For all these combinations, with good EBM 
data for its components, available are studies that 
document their blood pressure-lowering and or-
gan-protective efficacy: perindopril + amlodipine 
(STRONG) [28], ramipril + amlodipine (ATAR) 
[29], lisinopril + amlodipine (ALFESS, HAMLET) 
[30, 31], enalapril + lerkanidipine (FELT) [32].
Interestingly for practical reasons, the four listed 
combinations of ACE inhibitors + calcium antago-
nists can be differentiated due to the principles of 
chronotherapy of hypertension. Two ACE inhibitors, 
perindopril and lisinopril, are characterized by a 24-
hour antihypertensive effect similar to amlodipine, so 
when used in combination, they provide 24-h blood 
pressure control after morning administration in dip-
pers. Ramipril and enalapril, on the other hand, have 
shorter time of action, and even in combination with 
a long-acting calcium antagonist evening dosing may 
be useful in non-dippers.
Particularly important and frequently prescribed 
are SPCs containing an ACE inhibitor + thiazide/thi-
azide-like diuretics which are used to enhance the an-
tihypertensive effect of an ACE inhibitor by inducing 
hypovolaemia and increasing plasma renin activity 
by thiazide/thiazide-like diuretic, rather in patients 
with higher cardiovascular risk. Virtually all ACE 
inhibitors are available in combination with thiazide 
diuretic — hydrochlorothiazide. The only one cur-
rently available combination of an ACE inhibitor 
with preferred thiazide-like diuretic is SPC contain-
ing perindopril + indapamide, which is distinguished 
in the 2015 PSH guidelines because of three major 
clinical trials (ADVANCE, HYVET, PROGRESS) 
documenting the benefits of this combination in 
patients with concomitant diabetes mellitus, very 
elderly and with a history of stroke [33–35]. These 
are special indications reserved for this combination. 
A combination that is most commonly used in Po-
land — sartan + thiazide diuretic — has similar syn-
ergistic antihypertensive effect but should be used in 
patients with moderate and low cardiovascular risk. 
This combination is characterized by very good toler-
ance and it was evaluated in large clinical EBM trials 
demonstrating a reduction in cardiovascular risk in 
patients with left ventricular hypertrophy (LIFE) 
[36] and in patients with moderate cardiovascular 
risk (VALUE) [37]. As with ACE inhibitors, prac-
tically for all available sartans there are SPCs with 
hydrochlorothiazide, but two of them (valsartan + 
hydrochlorothiazide and telmisartan + hydrochloro-
thiazide) are particularly useful because of the pop-
ularity of these sartans. Unfortunately, no combina-
tion of a sartan with preferred thiazide-like diuretic is 
available in Poland, although in some countries such 
preparations are already available (combinations of 
sartans with chlortalidone).
The last primary SPC, a sartan + calcium antago-
nist, is less commonly used due to the lack of large 
EBM studies. However, combinations of valsartan 
with amlodipine (EX-FAST) [38] and telmisartan 
with amlodipine (TEAMSTA) [39] are worth re-
membering, especially in patients with metabolic 
disorders, due to a very good tolerance, favourable 
metabolic profile and documented antihypertensive 
effect. These combinations include components with 
proven efficacy in large clinical trials of patients with 
hypertension and high cardiovascular risk or coro-
nary artery disease. In controlled clinical trials with 
single-pill combination of telmisartan and amlodip-
ine, target blood pressure was achieved in 80% of 
patients with stage 1 or 2 hypertension and 50% of 
patients with stage 3 hypertension, with low inci-
dence of adverse events.
Another manifestation of advances in the treat-
ment with combined antihypertensive drugs is the 
arterial hypertension 2017, vol. 21, no. 3
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appearance of three-drug SPCs in Poland, which 
offers the possibility of intensifying the therapy using 
one tablet also in patients with higher baseline blood 
pressure values, including stage 3 hypertension. Both 
types of these combinations: ACE inhibitor + di-
hydropyridine calcium antagonist + thiazide-like 
diuretic (the only available SPC is perindopril + in-
dapamide + amlodipine) and older one, sartan + di-
hydropyridine calcium antagonist + thiazide diuretic 
(the only available SPC is valsartan + hydrochlothia-
zide + amlodipine) meet the criterion for optimum 
combination in uncomplicated hypertension. It is im-
portant to note that only for three-drug combination 
of perindopril + indapamide + amlodipine there are 
available analyses of randomized trials demonstrating 
the benefits in terms of cardiovascular risk reduction 
(ADVANCE) [40] and increase in the antihyperten-
sive effect (PIANIST) [41]. This combination has 
a unique pharmacokinetic profile resulting from dif-
ferent peak concentrations of its components, which 
provides a stable daily antihypertensive effect without 
sudden blood pressure drop in first hours after ad-
ministration, despite the activity of three drugs.
New SPCs for specific use
As a result of gradually increasing popularity of 
combined drugs, further SPCs that meet the criteria 
for optimal combination of antihypertensive drugs 
emerged in Poland in 2012–2017. Two of them pro-
vided the possibility of using SPC in patients who do 
not need or should not use RAA inhibitors.
The combination of a beta-blocker + calcium an-
tagonist (the only available SPC is bisoprolol + am-
lodipine) is particularly applicable in uncomplicated 
hypertension in younger patients requiring combi-
nation therapy, especially in women of childbearing 
potential. The advantage of this SPC, in addition to 
the antihypertensive effectiveness (BETAMLO) [42], 
is good tolerance resulting from the opposite chro-
notropic effect of both components, with a tendency 
to decrease heart rate [43]. The latter feature makes 
SPC containing bisoprolol + amlodipine also suitable 
for use in patients who have cardiac complications 
and are prone to tachycardia, basically in combi-
nation with an ACE inhibitor, since the three-drug 
SPC of an ACE inhibitor + dihydropyridine calcium 
antagonist + beta-blocker is not yet available. 
Another optimal combination of thiazide-like di-
uretics + calcium antagonists (the only one available 
SPC is indapamide + amlodipine) fills the gap in the 
possibility of using SPC in uncomplicated hyper-
tension in elderly patients requiring combination 
therapy, since both components are recognized in 
the ESH and PSH Guidelines as preferred drugs. 
The antihypertensive efficacy of this combination has 
been demonstrated in the EFFICIENT study [44] 
and, if intensification of treatment is necessary, it 
may be convenient to switch the patient to the avail-
able three-drug SPC of perindopril + indapamide + 
amlodipine.
Single-pill combination of a beta-blocker + thia-
zide diuretic (the only available SPC is nebivolol + hy-
drochlorothiazide) is recommended as a component 
of the therapy in patients with hypertension and heart 
failure rather than for starting antihypertensive ther-
apy. It is worth noting, however, that the presence in 
this combination of a beta-blocker with vasodilative 
properties, nebivolol, which has more favourable 
metabolic effect, mitigates traditional objections to 
the potential disadvantageous effects of long-term 
use of the combination of a beta-blocker + thiazide 
diuretic on carbohydrate or lipid metabolism.
The most recent combination of a beta-blocker 
+ ACE inhibitor (the only one available SPC is bi-
soprolol + perindopril) is dedicated to patients with 
hypertension complicated with coronary heart dis-
ease, because, according to 2015 PSH Guidelines, 
in these patients, regardless of myocardial infarction 
history, antihypertensive therapy should be based on 
such a combination. Sub-analysis of the EUROPA 
study [45] showed that patients with stable coronary 
heart disease using perindopril with a beta-blocker 
had a lower risk of myocardial infarction and cardio-
vascular death compared to those using a beta-blocker 
alone. It is worth noting that the SPC containing 
bisoprolol with perindopril is the only SPC regis-
tered simultaneously in the three largest population 
therapeutic indications: hypertension, coronary heart 
disease, and heart failure.
The Pol-Focus study [46] showed that the combi-
nation of a beta-blocker with ACE inhibitor is most 
commonly used in two-drug therapy by Polish doctors. 
Therefore, from practical point of view, this combi-
nation may be useful in younger patients with un-
complicated hyperkinetic hypertension (bisoprolol 
component) and already present symptoms of organ 
damage, e.g. left ventricular hypertrophy (perindopril 
component).
“Hybrid” SPCs of antihypertensive drugs 
with other drugs important  
for cardiovascular prevention
An interesting alternative is the SPC which contains 
antihypertensive agents along with other drugs used in 
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cardiovascular prevention: statins and acetylsalicylic acid. 
This direction in the evolution of pharmacothera-
py of hypertension is approaching the concept of 
“polypill”, but the difference consist in that it as-
sumes drug dosage control based on blood pressure 
and plasma cholesterol measurements in individual 
patients, while the “polypill” concept is targeted at 
societies of poor organization of healthcare system 
and assumes the improvement of cardiovascular risk 
at population level through the widespread use of the 
“polypill” containing low-doses of preventive drugs 
by all individuals above a certain global cardiovascu-
lar risk (e.g., based on age) without further detailed 
control and dosage modification.
Combinations of antihypertensive drugs with 
statins aim to simultaneously improve the two most 
important pharmacologically modifiable cardiovas-
cular risk factors: hypertension and hypercholes-
terolaemia. These factors additively increase global 
cardiovascular risk, and the number of people who 
are at the same time at risk of hypertension and hy-
percholesterolaemia is estimated in Poland at several 
million people. The first SPC of this type, available 
in Poland for many years, is the combination of ator-
vastatin + amlodipine. However, this SPC was char-
acterized by too low doses of atorvastatin available 
in this combination (10 or 20 mg). The relatively 
low popularity of this combination was also caused 
by the fact that statin in primary prevention was in-
dicated only in patients with hypertension and high 
cardiovascular risk, whereas it is patients with lower 
risk who are treated with monotherapy alone. The 
recently introduced combination of rosuvastatin + 
amlodipine is more likely to succeed because, after 
announcing the results of the JUPITER study [47], 
we know that statin therapy can be recommended in 
patients with hypertension and lower cardiovascular 
risk. In addition, doctors’ habits regarding the eve-
ning use of statins are progressively changing with 
respect to modern statins, atorvastatin and rosuvas-
tatin, whose efficacy in lowering LDL-cholesterol is 
the same irrespective of the time of administration. 
The decisive factor should be patients’ compliance, 
which can be improved by SPCs. Moreover, new 
recommendations for lipid lowering therapy and fur-
ther lowering of the target values of LDL-cholesterol 
will in practice favour more potent statins, such as 
rosuvastatin (20 mg or higher dose) or atorvastatin 
at higher doses (40 mg or 80 mg).
Very interesting “hybrid” SPC, which became 
available in Poland at the beginning of 2017, is 
a three-drug combination of a statin + ACE in-
hibitor + calcium antagonist (the only available 
SPC is atorvastatin + perindopril + amlodipine). 
Strong evidence for clinical benefits of this com-
bination was provided by the lipid shoulder of the 
ASCOT study [48] in which atorvastatin caused 
3-fold higher reduction of the risk of myocardial 
infarction in patients taking amlodipine and perin-
dopril than in those receiving atenolol and bendro-
flumethiazide, with comparable blood pressure and 
LDL-cholesterol control, suggesting the synergistic 
effects of atorvastatin, perindopril and amlodip-
ine. Similarly, significant relative reduction (33% 
vs. 2%) in cardiovascular mortality was observed 
in the atorvastatin group only in patients taking 
amlodipine + perindopril. Compared with the pre-
vious ones, this SPC meets the criteria for a combi-
nation of antihypertensive drugs and therefore may 
be used as one tablet formulation in patients with 
stage 2 hypertension with moderate to high car-
diovascular risk and concomitant metabolic and/or 
diabetic complications. Similar three-drug formu-
lations containing a calcium antagonist, an ACE 
inhibitor or sartan, and atorvastatin or rosuvastatin 
will be introduced into the Polish pharmaceutical 
market soon. 
The most recent interesting “hybrid” SPC is the 
combination of a statin + sartan (the only available 
SPC is rosuvastatin + valsartan) that can be success-
fully used in stage 1 hypertension with concomitant 
hypercholesterolaemia, especially in patients with 
metabolic syndrome, because it contains valsartan 
(NAVIGATOR) [49]. The combined use of sartans 
and statins also has a beneficial effect on reducing the 
risk of cardiovascular events (by approximately 40%) 
in patients with multiple comorbidities [50]. The 
NAVIGATOR study evaluating the effect of SPC 
of rosuvastatin + valsartan versus monotherapy on 
blood pressure and LDL-cholesterol levels has shown 
that the use of this SPC is associated with better 
control of both risk factors which can be explained 
by better adherence to medical recommendations (by 
34%) and greater therapeutic persistence.
Another option for “hybrid” SPC therapy is the 
combination of a beta-blocker + acetylsalicylic acid 
(the only available SPC is bisoprolol + ASA) for 
patients with ischaemic heart disease or heart fail-
ure regardless of the presence of hypertension. It 
has been argued to justify the use of this SPC that 
patients after myocardial infarction are likely to 
arbitrary discontinue ASA, while they are most per-
sistent with beta-blocker therapy. So far, this SPC 
has not become popular because of doctors’ habits 
related to the evening administration of ASA. It is 
dictated by the belief that ASA inhibits more effec-
tively platelet activation when administered in the 
evening. 
arterial hypertension 2017, vol. 21, no. 3
124 www.ah.viamedica.pl
Figure 2. Proposed new algorithm of new antihypertensive therapy
Future development of antihypertensive 
therapy with SPCs
In the opinion of the authors, the use of SPCs in 
antihypertensive therapy will increase in Poland, 
which may contribute to further improve of pressure 
control in our country. At present, almost all useful 
anti-hypertensive agents are available in the form of 
two-drug SPCs. The combination of a sartan with 
beta-blocker for hypertensive patients with cardiac 
hypertrophy who do not tolerate ACE inhibitors and 
a “hybrid” SPC of an ACE inhibitor + statin are still 
expected. Three-drug combinations: ACE inhibitor + 
beta-blocker + calcium antagonist, for patients with 
hypertension and coronary artery disease requiring 
intensive therapy, and ACE inhibitor + beta-blocker 
+ statin, which will enable single-pill combination 
therapy for most patients, would also be useful. 
However, in order for these favourable trends to 
gain momentum, two conditions must be met both 
by the group of experts who develop the guidelines 
for treatment of hypertension and representatives of 
authorities responsible for registration process and 
approving indications for the use of specific drugs, 
e.g. SPCs. 
The first of these conditions is a change in the phi-
losophy of the antihypertensive treatment algorithm 
consisting in the assumption that pharmacotherapy 
of hypertension be initiated with combination ther-
apy, with preference for SPC for most patients, and 
that identified should be those patients who are likely 
to benefit from monotherapy (stage 1 hypertension 
with low global cardiovascular risk). As mentioned 
above, analysis of ESH experts’ lectures (Volpe, Wil-
liams) at this year’s ESH 2017 Congress in Milan 
suggests that such changes are considered [22] and 
that new PSH recommendations will also follow this 
direction (Figure 2).
It is more difficult to fulfil the second condi-
tion because it requires a change of approach to 
the indications for the use of SPC by officials, tak-
ing into account expert opinions. Currently, only 
two combination drugs, perindopril + amlodipine 
in substandard doses, as described above, and some 
formulations of perindopril + indapamide at lower 
doses are indicated for initiation of antihypertensive 
therapy. Most SPCs have so-called “add-on indi-
cation”, which means the requirement of lack of 
control with one component alone, or so-called “sub-
stitute indication”, that means the requirement of 
previous adequate control of blood pressure on both 
components of SPC. It would be logical to give all 
SPC indications for the initiation of antihypertensive 
therapy in patients with stage 2 hypertension (i.e., 
according to the recommendations of the scientific 
societies), since there is nothing to prevent a doctor 
from prescribing any two antihypertensive drugs in 
combination as starting therapy. Such a solution is 
supported by not only by medical but also economic 
reasons.
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